“I’ve been fighting Crohn’s disease with a biologic medication for as long as I can remember. When I turned 26, I switched health care plans, and the biologic that I had been taking for years wasn’t covered anymore, but my doctor knew of a biosimilar that would be. So we made the change, and now I don’t pay anything for my infusions. I hope that others can have the same access and that more biosimilars will become available on insurance plans in the future. I can’t imagine not having access.” — Eileen, 28, New York, NY.
Savings from biosimilars for patients like Greg totaled $8 billion in 2020 and are projected to save $133 billion over the next five years.